Drug intelligence / Profile preview

anastrozole + cyclophosphamide + epirubicin + exemestane + fluorouracil + zoledronic acid

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy regimen used in breast cancer treatment. This regimen combines multiple therapeutic approaches: - Chemotherapy agents (cyclophosphamide, epirubicin, fluorouracil) - Hormone therapy (anastrozole, exemestane) - Bone-targeted therapy (zoledronic acid) The combination aims to provide comprehensive treatment by targeting cancer cells through different mechanisms while also addressing potential bone complications.

Targets

TS (Thymidylate synthase)CYP19A1 (Aromatase)TOP2A (DNA topoisomerase II)DNAFDPS (Farnesyl pyrophosphate synthase)

Beyond the preview

Go deeper on anastrozole + cyclophosphamide + epirubicin + exemestane + fluorouracil + zoledronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anastrozole + cyclophosphamide + epirubicin + exemestane + fluorouracil + zoledronic acid.

Explore the full profile